US FDA reverses course on Regenxbio’s rare-disease gene therapy, backs accelerated approval bid

This is a summary. Read the complete story at Investing.com below.

Related Stories

stocksabout 6 hours ago

CIBC stands out as the value pick among Canada’s major bank stocks

Investing.com

stocksabout 9 hours ago

Saudi Arabia stocks lower at close of trade; Tadawul All Share down 0.26%

Investing.com

stocksabout 9 hours ago

TSX miners to watch next week as analysts flag further upside

Investing.com